Cannabidiol Oil

Verify with FDA CVM →

12 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
2
Deaths Reported
1670.0%
Death Rate

Active Ingredients

Cannabidiol Oil

Administration Routes

OralUnknown

Species Affected

Dog 11
Cat 1

Most Affected Breeds

Spitz - German Pomeranian 1
Shepherd Dog - German 1
Dalmatian 1
Hound (unspecified) 1
Spaniel - Cocker American 1
Retriever - Labrador 1
Shiba Inu 1
Shih Tzu 1
Retriever - Golden 1
Poodle (unspecified) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Pruritus 2
Decreased appetite 2
Anorexia 2
Polydipsia 2
Emesis (multiple) 2
Leucocytosis NOS 2
Anaemia NOS 2
Death by euthanasia 2
Lack of efficacy - NOS 2
Limb weakness 2
Diarrhoea 1

Outcome Breakdown

Outcome Unknown
6 (50.0%)
Recovered/Normal
2 (16.7%)
Ongoing
2 (16.7%)
Euthanized
2 (16.7%)

Data Summary

Metric Value
Total adverse event reports 12
Reports involving death 2
Case-fatality rate (reported events) 1670.0%
Distinct species in reports 2
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Cannabidiol Oil Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 12 adverse event reports referencing Cannabidiol Oil, including 2 reports in which the animal died — a 1670.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Cannabidiol Oil. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Cannabidiol Oil reports are Dog (11 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Spitz - German Pomeranian (1), Shepherd Dog - German (1), Dalmatian (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Cannabidiol Oil are Lethargy (see also Central nervous system depression in 'Neurological') (4), Pruritus (2), Decreased appetite (2), Anorexia (2). Of the 12 reports with a coded outcome, Outcome Unknown is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Cannabidiol Oil.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial